Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Mineralys Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RADNOR, PA., AUG. 13, 2026 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND ALDOSTERONE-RELATED ADVERSE OUTCOMES IN COMORBID CONDITIONS SUCH AS CHRONIC KIDNEY DISEASE, OBSTRUCTIVE SLEEP APNEA AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, ANNOUNCED TODAY THAT, ON AUGUST 10, 2026, A MAJORITY OF THE INDEPENDENT DIRECTORS OF MINERALYS' BOARD OF DIRECTORS GRANTED AN INDUCEMENT STOCK OPTION AWARD COVERING 135,000 SHARES AND AN INDUCEMENT RESTRICTED STOCK UNIT AWARD COVERING 102,400 SHARES OF MINERALYS COMMON STOCK TO DR. TERRY FERGUSON, MINERALYS' NEWLY APPOINTED CHIEF MEDICAL OFFICER.

MINERALYS THERAPEUTICS REPORTS INDUCEMENT AWARD UNDER NASDAQ LISTING RULE 5635(C)(4)

 PDUFA TARGET DATE OF DECEMBER 22, 2026 FOR LORUNDROSTAT; COMMERCIAL PREPARATIONS ON-TRACK FOR LAUNCH UPON APPROVAL   APPOINTS ACCOMPLISHED CARDIOVASCULAR MEDICINE EXECUTIVE DR. TERRY FERGUSON AS CHIEF MEDICAL OFFICER TO LEAD THE COMPANY'S MEDICAL AND LATE-STAGE CLINICAL ACTIVITIES   STRENGTHENED BALANCE SHEET AND ENHANCED THE LONG-TERM ECONOMICS OF LORUNDROSTAT THROUGH STRATEGIC FINANCING INITIATIVES AND THE REPURCHASE OF THE TANABE ROYALTY OBLIGATION   CONFERENCE CALL TODAY AT 4:30 P.M. ET  RADNOR, PA.

MINERALYS THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

RADNOR, PA., JULY 27, 2026 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND ALDOSTERONE-RELATED ADVERSE OUTCOMES IN COMORBID CONDITIONS SUCH AS CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, ANNOUNCED TODAY THAT (1) ON JULY 17, 2026, THE COMPENSATION COMMITTEE OF MINERALYS' BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED AN INDUCEMENT STOCK OPTION AWARD COVERING 14,880 SHARES AND AN INDUCEMENT RESTRICTED STOCK UNIT AWARD COVERING 11,160 SHARES OF MINERALYS COMMON STOCK TO A NEW NON-EXECUTIVE EMPLOYEE, AND (2) ON JULY 20, 2026, THE COMPENSATION COMMITTEE GRANTED AN INDUCEMENT STOCK OPTION AWARD COVERING 27,920 SHARES AND AN INDUCEMENT RESTRICTED STOCK UNIT AWARD COVERING 20,940 SHARES OF MINERALYS COMMON STOCK TO ANOTHER NEW NON-EXECUTIVE EMPLOYEES.

MINERALYS THERAPEUTICS REPORTS INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)

 LORUNDROSTAT WAS ASSOCIATED WITH SIGNIFICANT REDUCTIONS IN HEART FAILURE RISK BIOMARKERS IN A PROTEOMIC ANALYSIS OF DATA FROM PARTICIPANTS WITH UNCONTROLLED HYPERTENSION 

MINERALYS THERAPEUTICS PRESENTS LATE-BREAKING DATA ON LORUNDROSTAT AND HEART FAILURE RISK BIOMARKERS AT THE ENDOCRINE SOCIETY ANNUAL MEETING (ENDO 2026)

RADNOR, PA., JUNE 08, 2026 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND RELATED COMORBIDITIES SUCH AS CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, TODAY ANNOUNCED THAT MANAGEMENT WILL BE PARTICIPATING IN THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE BEING HELD IN MIAMI ON JUNE 8-10, 2026.

MINERALYS THERAPEUTICS TO PARTICIPATE IN THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

LATE-BREAKING PRESENTATION REPORTS A PROTEOMIC ANALYSIS OF HEART FAILURE BIOMARKERS DURING LORUNDROSTAT TREATMENT LATE-BREAKING PRESENTATION REPORTS A PROTEOMIC ANALYSIS OF HEART FAILURE BIOMARKERS DURING LORUNDROSTAT TREATMENT

MINERALYS THERAPEUTICS TO PRESENT LATE-BREAKING DATA ON LORUNDROSTAT AT THE ENDOCRINE SOCIETY ANNUAL MEETING (ENDO 2026)

RADNOR, PA., JUNE 03, 2026 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND RELATED COMORBIDITIES SUCH AS CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, ANNOUNCED TODAY THE PRICING OF AN UNDERWRITTEN OFFERING OF 5,660,378 SHARES OF ITS COMMON STOCK AT A PRICE OF $26.50 PER SHARE. THE AGGREGATE GROSS PROCEEDS TO MINERALYS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER ESTIMATED OFFERING EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $150.0 MILLION. ALL OF THE SECURITIES TO BE SOLD IN THE OFFERING ARE TO BE SOLD BY MINERALYS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JUNE 4, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

MINERALYS THERAPEUTICS ANNOUNCES PRICING OF $150 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

REPURCHASE OF LORUNDROSTAT ROYALTY OBLIGATION IN TANABE LICENSE AGREEMENT FOR $200 MILLION UPFRONT AND UP TO $100 MILLION ONCE CERTAIN COMMERCIAL MILESTONES ARE MET 

MINERALYS THERAPEUTICS ANNOUNCES REPURCHASE OF ROYALTY OBLIGATIONS IN TANABE LICENSE AGREEMENT AND CONCURRENT FINANCING

 POST HOC ANALYSIS FROM PIVOTAL LAUNCH-HTN TRIAL SHOWS STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL REDUCTIONS IN BLOOD PRESSURE IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE 

MINERALYS THERAPEUTICS PRESENTS NEW DATA FROM THE PHASE 3 LAUNCH-HTN TRIAL OF LORUNDROSTAT IN PARTICIPANTS WITH HYPERTENSION AND CHRONIC KIDNEY DISEASE AT EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION (ESH 2026)

RADNOR, PA., MAY 27, 2026 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND RELATED COMORBIDITIES SUCH AS CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, TODAY ANNOUNCED THAT MANAGEMENT WILL BE PARTICIPATING IN THE JEFFERIES 2026 GLOBAL HEALTHCARE CONFERENCE BEING HELD IN NEW YORK ON JUNE 2-4, 2026.

Mineralys Therapeutics, Inc.

MLYS

Price

Financial Reports

No items found.

Press Releases

Mineralys Therapeutics, Inc.

MLYS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MLYS